Enhertu 100mg Injection contains the active ingredient Trastuzumab deruxtecan, a targeted therapy used to treat certain types of breast and stomach cancers. Enhertu 100 mg uses in adult patients with Enhertu for HER2-positive breast cancer or HER2-positive gastric cancer. This medicine is not recommended for individuals under 18 years of age. The Enhertu dosing infusion every 3 weeks is the standard schedule, meaning patients typically receive the medicine once every three weeks under the supervision of a healthcare professional.

Enhertu works by binding to HER2-positive cancer cells and delivering a cytotoxic agent directly into them, which helps destroy the cancer cells while minimizing damage to surrounding healthy tissues. The standard Enhertu dosing involves an infusion every 3 weeks, administered by a healthcare professional in a clinical setting.

Patients and doctors often compare Enhertu vs Kadcyla to determine the most suitable HER2-targeted treatment, as both are used for HER2-positive breast cancer but differ in formulation, mechanism, and clinical outcomes.

Like all medicines, Enhertu may cause side effects. Common Enhertu infusion adverse reactions can include nausea, vomiting, fatigue, decreased appetite, and infusion-related reactions. More serious side effects may involve lung or heart problems, so regular monitoring is important.

Enhertu cost In India, the Enhertu Injection price can vary depending on location and supplier. The Enhertu 100 mg price in India and the Enhertu price per month may be high, making it important for patients to discuss financial assistance programs with their doctor or pharmacist.

Enhertu injection uses include the treatment of HER2-positive metastatic breast cancer in patients who have already received other anti-HER2 therapies, as well as HER2-positive advanced gastric cancer in patients previously treated with a trastuzumab-based regimen. Enhertu 100mg Injection Price Varies by retailer and location. You can Buy Enhertu 100mg Injection online at MrMed For Affordable Prices.

Enhertu 100 mg injection uses are 

• Treats HER2-positive breast cancer that is metastatic or unresectable for patients who have had prior anti-HER2 treatments.

• Effective for HER2-low metastatic breast cancer after prior chemotherapy.

• Treats HER2-mutated non-small cell lung cancer (NSCLC) that is metastatic or unresectable following prior treatment.

• Used for HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma after prior trastuzumab-based therapy.

• For HER2-positive (IHC 3+) metastatic solid tumours when no other satisfactory treatments are available.

Enhertu 100mg Injection works in a targeted way to treat certain cancer cells. It is made up of two main parts:

1. Monoclonal Antibody: This part of the medication specifically attaches to cancer cells that have the HER2 protein on their surface. These are known as HER2-positive cancer cells, which are common in some breast and stomach cancers.

2. DXd (Drug Conjugate): This is the other active component of Enhertu 100 mg Injection. DXd is a powerful substance that can kill cancer cells.

Enhertu 100 mg Injection finds and attaches to HER2-positive cancer cells. Once attached, it delivers the DXd directly into these cancer cells. The DXd then works to kill these cells from the inside. This targeted approach helps attack the cancer cells while sparing many healthy cells in the body.

Inform your physician about all the prescribed medicine, over-the-counter medications, nutritional or vitamin supplements, and herbal supplements you have taken before. Certain medications may interact with Enhertu 100mg Injection and can cause undesirable side effects. 

• Store in the refrigeratorat refrigerator between 2°C to 8°C.

• Do not freeze.

• It should be kept away from children and pets.

Enhertu 100mg Injection is administered through an intravenous (IV) infusion by a healthcare provider every three weeks. Before each treatment, you may receive medication to prevent nausea and vomiting. If you have an infusion-related reaction, the infusion may be slowed, paused, or permanently stopped for severe reactions. If you miss a dose, it's important to contact your healthcare provider immediately to reschedule. The number of treatments will depend on your healthcare provider's assessment. Your healthcare Provider will decide the Enhertu 100mg dosage and administration.

Enhertu 100mg Injection Side effects are unwanted symptoms caused by medicines. Even though all medicines cause side effects, not everyone gets them. 

Serious:

• Severe allergic reactions (rashes, itching, difficulty in breathing, fever)

Common:

• Nausea (feeling sick), vomiting

• Tiredness

• Decreased appetite

• Blood tests showing decreased red or white blood cells or platelets

• Hair loss

• Diarrhoea

• Constipation

• Blood tests showing increased levels of the liver enzymes such as transaminases

• Pain in muscles and bones

• Weight loss

• Fever

• Abdominal (belly) pain

• Infections of the nose and throat, including flu-like symptoms

• Headache

• Blisters in or around your mouth

• Cough

• Blood tests showing low blood potassium levels

• Indigestion

• Breathing difficulties

• Swelling of ankles and feet

• Nosebleed

• Altered/bad taste in the mouth

• Infection of the lungs

• Regularly monitor lung and liver functions with your doctor while taking Enhertu 100mg Injection due to possible side effects.

• Both women and men should use effective contraception during treatment.

• Women should continue birth control for at least 7 months after the final dose.

• Men should continue birth control for 4 months after completing treatment to avoid risks to partners who may become pregnant.

• Consult your doctor about the most suitable contraceptive methods and inform them before stopping contraception.

• Male patients should note that Enhertu 100mg Injection may affect fertility.

• Men are advised not to father a child for 4 months after treatment.

• Discuss sperm preservation options with your doctor before starting the medication.

1. Daiichi Sankyo UK Ltd, Electronic Medical Compendium (EMC),[Revised on July 2023][Accessed on Jan 2024] https://www.medicines.org.uk/emc/files/pil.12135.pdf

2. Daiichi Sankyo, Inc, Food and Drug Safety Administration (FDA), [Revised on Jan 2021] [Accessed on Jan 2024] https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761139s011lbl.pdf

3. KD Tripathi, Essentials of Medical Pharmacology, Chemotherapy For Neoplastic Diseases, 7th edition, 2013, 930.

4. Goodman & Gilman's, The Pharmacological Basis of Therapeutics, Pharmacotherapy for Neoplastic Diseases, 12th edition, 2011, 1206.

5. https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu_Med&inline=true

6. https://www.enhertu.com/